[PRESS RELEASE:] REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
08 February 2024
REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis). REPROCELL will soon...
End of 2023 Newsletter
15 December 2023
The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...
REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
24 October 2023
On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA). Preclinical data from fresh human tissue “The purpose of this study...
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
01 June 2023
01 June 2023, Glasgow, UK and Daresbury, UK: REPROCELL today announces the launch of a new commercial service, Pharmacology-AI. The launch follows the completion of one of the first EXCELERATE projects, by the Hartree National Centre for Di...
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
09 December 2022
Silo Pharma, Inc. has announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. Conducted in partners...
Building economic resilience and unleashing productivity through digital innovation
09 November 2022
UK enterprises are facing a number of disruptive forces that necessitate transformation at pace – macro-economic challenges, socio-political challenges, and the focus on our own resilience. Industries from across the country are in the grip...
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine learning. Glasgow, UK and Daresbury, UK: REPRO...
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022
Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound, RCD405, with drugs that are currently used to t...
Life science after lockdown: SPS returns for 2022
15 August 2022
Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and events promoting the best practices in s...
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
08 March 2022
Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies. The paper, titled "Com...